Risks of Postendoscopic Retrograde Cholangiopancreatography Pancreatitis and Hyperamylasemia After Endoscopic Papillary Balloon Dilation: A Retrospective Analysis

Abstract

It is currently unclear whether endoscopic papillary balloon dilation (EPBD) is associated with increased severe postendoscopic retrograde cholangiopancreatography pancreatitis (PEP)-related morbidity owing to conflicting reports. This study aimed to investigate whether EPBD increases the risk of PEP and hyperamylasemia. Clinical data of patients with choledocholithiasis, treated at the Second Affiliated Hospital of Harbin Medical University from January 2015 to December 2016 were analyzed. Patients were divided into the EPBD group and endoscopic sphincterotomy (EST)+EPBD group, and their characteristics and PEP and hyperamylasemia incidences were compared. Incidences related to dilated balloon diameter were also analyzed. There were no significant differences in patient characteristics and the incidences of PEP (2.6% vs. 0%; P = 0.257) and hyperamylasemia (4.4% vs. 5.6%; P = 0.954) between the 2 groups. Results were similar even with different balloon dilatations. EPBD without endoscopic sphincterotomy did not increase the risk of PEP and hyperamylasemia. It is a safe option for choledocholithiasis patients.

The correlation between postoperative complications of ERCP and quality of life after discharge in patients with choledocholithiasis

“…Common complications include pancreatitis, perforation, hemorrhage, cholangitis, etc., but also include acute cholecystitis, related cardiopulmonary complications, duodenal hematoma, and other complications with a low incidence. In this study, it was found that the incidence of hyperamylase was the highest (9.3%), followed by acute pancreatitis (5.7%), and then cholecystitis (2.6%), which is similar to previously reported results (12)(13)(14)25). Quality of life can fully reflect the patient's health status.…”

Secrets, puzzles and mysteries of macroamylasemia

“…Несмотря на вышеприведенные данные, некоторые специалисты смогли доказать безопасность выполнения хирургических манипуляций на ПЖ именно благодаря отсутствию роста МАЕ. Так, S. Liu et al подчеркивают безопасность проведения РХПГ на основании отсутствия взаимосвязи между распространенностью тяжелого постэндоскопического РХПГ-ассоциированного панкреатита среди пациентов, перенесших эндоскопическую баллонную дилатацию большого дуоденального сосочка или эндоскопическую сфинктеротомию в сочетании с баллонной дилатацией этого анатомического образования (2,6% vs 0%; р=0,257) [37]. Исследователи не выявили статистически значимой взаимосвязи между выполнением указанного лечебно-диагностического вмешательства и развитием МАЕ (4,4% vs 5,6%; р=0,954), признав эндоскопическую баллонную дилатацию большого дуоденального сосочка безопасным методом лечения холедохолитиаза [37].…”